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ment, cystic fibrosis, hematologic-metabolic syndromes, overweight, and psycho-
social problems. A comparison between adult and pediatric HTAs was undertaken
for 222 reports published in 2007-2008. RESULTS:Whereas the most common con-
ditions studied in adults were cancer, cardiovascular disorders and rheumatologi-
cal disorders, diseases most commonly studied in children were asthma, autism,
cystic fibrosis and diabetes. In addition to differences between adults and children
related to measurement, analysis and the availability of evidence, the social, legal
and ethical issues that influence decision-making are unique for children due to
their vulnerability and lack of autonomy. CONCLUSIONS: As HTA increasingly
becomes the basis for decision-making, the challenges in applying HTA to child
health must be considered to ensure equity in health care policy.
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PRACTICAL CONSIDERATIONS FOR ESTIMATING SAMPLE SIZE AND STUDY
DURATION IN PREGNANCY EXPOSURE REGISTRIES
Covington D, Churchill P, McKain L
PPD, Wilmington, NC, USA
OBJECTIVES: Pregnancy exposure registries are important tools to evaluate drug
safety in pregnancy. Because pregnancy registries are unique, they present chal-
lenges in estimating critical factors impacting sample size and study duration,
including accrual, retention, and live birth (LB) rates. The objective of this study is
to examine these 3 factors in ongoing pregnancy registries and estimate impact on
sample size and enrollment duration. METHODS: We examined published data
from pregnancy registries identified through the internet and literature searches.
Of the 58 pregnancy registries identified, 21 (36%) had published data available. Of
the 21, only 18 published sufficient detail to allow calculation of LB, retention, and
accrual rates. RESULTS: The average duration for registries with published data
available was 8.8 years compared to 2.7 years for registries with no published data.
Themedian LB rate for single-drug registries was 88% (range: 62-95%), which is 45%
higher than the population rate. The median retention rate was 73% (range: 37%-
99%). The median accrual per year was 81.9 (range: 5.3-296). Using the median
rates, 422 pregnancies would need to be enrolled over 5 years to achieve sufficient
power to rule out a twofold increase in risk of birth defects. The rates varied from
a low of 320 pregnancies enrolled over 1.1 years to a high of 570 pregnancies en-
rolled over 100 years. Factors impacting the variability of rates included drug indi-
cation, patient population, design, data source, location, and recruitment and re-
tention activities. CONCLUSIONS: The LB rate was the least volatile of the factors
examined and the accrual ratewas themost volatile. Using the observed rates from
other pregnancy registries as a guide may aid in determining sample size and
enrollment timelines, but these rates are highly variable. Careful consideration
should also be given to factors that could impact these rates.
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THE DISABILITY AND QOL WITH THE ELDERLY
Tazaki M, Yamaguchi T
TOHO University, Tokyo, Japan
OBJECTIVES: The aims of this research were 1) to develop the Japanese version of
the World Health Organization Disability Assessment Schedule II (WHODAS II),
which was created to evaluate levels of disabilities based on the International
Classification of Functioning; 2) to evaluate the psychometric properties of the
instrument to check its validity and reliability; 3) to evaluate its applicability to the
elderlywith andwithout disabilities. In this study, a proxy-administered version of
36-items, an interviewer-administered version of 36-items, and the WHO Quality
of Life (QOL) were delivered.METHODS: At first, the preliminary Japanese version
of the WHODAS II was produced after incorporating feedback from a qualitative
study. Then, a preliminary study was conducted with 45 elderly people over 65
years old with various disabilities at two nursing homes in Tokyo (interviewer
administered) and with 30 professional caregivers at the homes (proxy
administered). RESULTS: The number of participants in the interview version of
the assessment was 45 (male 10: female 35), with a mean age of 80.7 (SD 7.3). The
mean age of the elderly who was cared for by those professional care givers who
answered the proxy versionwas 86.1(SD 6.8). The globalWHODAS IImean score for
the proxy-administered group was 100.5 (SD  31.0), and for the interviewer-ad-
ministered group was 58.5 (SD  19.8). The recommended standard Cronbach’s
alpha coefficient for each domain of the WHODAS II was achieved. For the inter-
viewer-administered group, there was a moderately strong, negative correlation
between the QOL score and theWHODAS score (r -0.62, P 0.01). CONCLUSIONS:
It was found that the Japanese version of the WHODAS II has sufficient reliability,
validity, and applicability for use with elderly with various disabilities, and it was
also found that the more severe the disability, the lower the QOL.
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ADVANCED DISEASE IN OVARIAN CANCER: CLINICAL AND ECONOMIC
OUTCOMES WITHIN HOSPITAL INPATIENT SETTINGS
Tate WR, Skrepnek GH, Alberts DS
The University of Arizona, Tucson, AZ, USA
OBJECTIVES: To assess the characteristics of inpatient mortality and charges as-
sociated with advanced disease in ovarian cancer in the United States from
2005-2009. METHODS: Nationally-representative hospital discharge records from
Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utiliza-
tion Project (H-CUP) Nationwide Inpatient Sample (NIS) from 2005-2009 were used
in this retrospective cohort analysis. Cases18 years of agewith advanced ovarian
cancer were selected. Variables analyzed included sites of metastases, patient de-
mographics, hospital characteristics, lengths of stay, primary payer, and Elix-
hauser comorbidity risk-adjustment. Outcomes of mortality and charges were as-
sessed via multivariate logistic and gamma regression, respectively, yielding odds
ratios (OR) or exponentiated beta coefficients (exp(b)). RESULTS: Overall, 352,319
inpatient ovarian cancer cases were observed from 2005-2009, with an inpatient
mortality rate of 5.3% and a national bill of $13.1 billion. Advanced disease repre-
sented 50.5% of cases, averaging 64.1 (13.4) years of age, an inpatient mortality
rate of 7.2%, and average charges of $46,123 (60,396) or 61.1% of the national bill.
The most commonmetastatic sites were gastrointestinal (60.5%), lung/respiratory
(15.4%), liver/digestive organs (18.4%), lymph (11.9%), and genitourinary (4.4%).
Multivariate analyses indicated significantly (p0.05) higher odds of inpatientmor-
tality with metastases to the liver/digestive organs (OR1.28), lung/respiratory
tract (OR1.66), central nervous system (OR1.62), and kidney (OR1.84). Other
key comorbidities associated with increased inpatient mortality included heart
failure, coagulopathy, liver disease, fluid/electrolyte disorders, neurological disor-
ders, pulmonary circulation disorders, renal failure, and weight loss. Significantly
higher inpatient charges were found with metastases to the skin (exp(b)1.13),
liver/digestive organs (exp(b)1.03), gastrointestinal tract (exp(b)1.25), lymph
nodes (exp(b)1.23), and genitourinary system (exp(b)1.21). CONCLUSIONS: Ad-
vanced disease is found in approximately half of inpatient ovarian cancer cases,
incurring a large burden of illness. The increased understanding ofmetastatic sites
and complications remains imperative to improving treatment and patient out-
comes.
PCN2
DEPRESSION TREATMENT IN INDIVIDUALS WITH PHYSICAL ILLNESSES: A
COMPARISON BETWEEN CANCER AND CARDIO-METABOLIC CONDITIONS
Rane PB1, Sambamoorthi U1, Madhavan S2
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of
Pharmacy, Morgantown, WV, USA
OBJECTIVES: Similar challenges are encountered in management of depression
among individuals with cancer and cardio-metabolic conditions; with presence of
high prevalence of diagnosed depression, negative impact of depression on health
outcomes, and competing demands in clinical care encounters, in both the condi-
tions. Additionally, there has been a lack of robust evidence from clinical trials on
the effectiveness of depression treatment on physical illness outcomes in both
cancer and cardio-metabolic conditions. Thus the objectives of this study were to
compare depression treatment rates among individuals with self-reported depres-
sion and cancer or cardio-metabolic conditions, and to examine the association
between depression treatment and presence of cancer diagnosis after controlling
for demographic, socio-economic, access to care, health status, and lifestyle
characteristics.METHODS: The study used a retrospective cross-sectional design.
Data from multiple years of the Medical Expenditure Panel Survey (MEPS), a na-
tionally representative household survey on healthcare utilization and expendi-
tures was used. Study sample consisted of adults aged 21 or older with self-re-
ported depression and cancer (N  528), or self-reported depression and diabetes,
heart disease or hypertension (N  1643). Depression treatment comprised of any
use of antidepressants and/or any use of mental health counseling services.
RESULTS:Treatment rates for depressionwere 78.0% and 81.7% among individuals
with cancer and cardio-metabolic conditions, respectively. After controlling for
demographic- and socio-economic characteristics, access to care, health status,
lifestyle risk factors, and number of physician visits; individuals with cancer were
less likely to report treatment for depression (AOR 0.67; 95% Confidence Interval
((0.49, 0.92), p  0.01) compared to individuals with cardio-metabolic conditions.
CONCLUSIONS: Our findings suggest that presence of cancer may be associated
with a lower likelihood of receiving depression treatment, perhaps due to cancer
being a clinically dominant condition.
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RELATIONSHIP BETWEEN COMORBIDITIES AND LATE-STAGE PROSTATE
CANCER DIAGNOSIS AMONG MEN IN FLORIDA
Xiao H1, Tan F2, Gwede C3, Goovaerts P4, Huang Y5, Ali A1, Adunlin G1
1Florida A&M University, Tallahassee, FL, USA, 2Indiana University-Purdue University,
Indianapolis, IN, USA, 3Moffitt Cancer Center, Tampa, FL, USA, 4BioMedware, Inc, Ann Arbor,
MI, USA, 5Florida Department of Health, Tallahassee, FL, USA
OBJECTIVES:Comorbidity impacts the treatment options and prognosis of prostate
cancer. This study examined association of major types of comorbidity with late-
stage prostate cancer in Florida.METHODS: The studywas a retrospective analysis
of Florida Cancer Registry data. A total of 60,497 prostate cancer cases diagnosed
between 2001-2007 were included. Individual-level data included demographics,
primary health insurance payer and tumor stage at diagnosis. Census-tract level
data included socioeconomic status extracted from Census 2000 and linked to
individual cancer data. County-level provider-to-case ratio was computed based
on data files provided by the Florida Department of Health. Comorbidity was com-
puted following Elixhauser Index. Multi-level logistic regressionwas used to exam-
ine associations of these factors with late-stage prostate cancer diagnosis.
RESULTS: Among individual level factors, late-stage diagnosis was significantly
and independently associated with being black, unmarried, current smoker, unin-
sured, and presence of comorbidities. No associationwas found between late-stage
diagnosis and year of diagnosis except for 2006. People with public insurance and
diagnosed in hospitals were associated with lower likelihood of late-stage diagno-
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sis. Late-stage diagnosis was associated with lower median income and lower
provider-to-case ratio. Among all comorbidity conditions, presence of congestive
heart failure, paralysis, renal failure, metastatic cancer, coagulation deficiency,
weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemias,
alcohol abuse, pneumococal pneumonia, protein calorie malnutrition, distur-
bances of amino acidmetabolism, brain and other neurological disorders were risk
factors of late-stage diagnosis. CONCLUSIONS: Overall, late-stage diagnosis was
associated with factors that suggest lack of access to care. Although comorbidity is
often associated with increased health care utilization, the association of comor-
bidity with late-stage prostate cancer diagnosis suggests that individuals with sig-
nificant comorbiditymaynot be offered routine prostate cancer screening, and that
focus is directed toward management of presenting health problems rather than
routine cancer screening.
PCN4
EFFECT OF TREATMENT DELAYS ON LATE-STAGE PROSTATE CANCER
SURVIVAL
Adunlin GB, Xiao H, Ali AA
Florida A&M University, Tallahassee, FL, USA
OBJECTIVES: To examine whether delay in receiving treatment for late-stage pros-
tate cancer were related to adverse survival outcomes. METHODS: The Florida
Cancer Data Systemwas used to extract information onmen diagnosed with pros-
tate cancer with their demographics, primary health insurance payer at diagnosis,
treatment and all-cause death. Census-tract level socioeconomic status was ex-
tracted from Census 2000 and linked to cancer data. Comorbidity following Elix-
hauser Index and County-level provider-to-case ratio were computed. Overall sur-
vival wasmeasured as the number of days between initiation of first treatment and
death? Descriptive statistics were performed. Log-rank test was conducted to eval-
uate the relationship between predictor variables and survival. Kaplan–Meier esti-
mation was used to generate survival curves. Cox proportional hazards regression
model was used for to produce hazard ratios (HRs) and 95% confidence intervals
after controlling for covariates. RESULTS: Between October 1, 2001 and December
31, 2007, 10330 men, average age of 69 had complete vital status, date of treatment
and survival time greater than zerowere diagnosedwith late-stage prostate cancer
in Florida. Of these, 3331 (32 %) died. Themedianswere 286 days for survival and 39
days between the date of diagnosis and initiation of first treatment. Treatment
delay was more likely to increase survival. Compare to patients in active surveil-
lance, those receiving other treatment options had an increased overall survival.
Patients with comorbidities, diagnosed at older age, or uninsured were more likely
to haveworse survival. Living in a census tract with higher educational attainment
was associated with better overall survival. CONCLUSIONS: Further investigation
is needed to understand the reasons for disparity in prostate cancer survival so that
interventions can be implemented to increase prostate cancer screening. The as-
sociation between changes in patterns of care, and treatment delay need to be
elucidated.
PCN5
CANCER DURING PREGNANCY: CLINICAL AND ECONOMIC CHARACTERISTICS
ASSOCIATED WITH INPATIENT CASES IN THE UNITED STATES
Chinthammit C, Skrepnek GH
University of Arizona, College of Pharmacy, Tucson, AZ, USA
OBJECTIVES: To assess clinical characteristics and national charges for maternal
hospitalizations and complications associated with cancers during pregnancy in
the United States. METHODS: This population-based retrospective study of inpa-
tient preterm complications or delivery and economic burden associatedwith can-
cer diagnosed during pregnancy utilized Agency for Healthcare Research andQual-
ity (AHRQ) Healthcare Cost and Utilization Project (H-CUP) Nationwide Inpatient
Sample (NIS) data from 2005-2009. Inclusion criteria included 18 years, any ma-
ternal diagnoses or procedures on record, and any diagnosis of cancer. Descriptive
analyses were conducted to report the most common forms of cancer, complica-
tions of pregnancy, and comorbidities. Generalized linear models including multi-
variate logistic and gamma regressions were employed to assess outcomes of pre-
term births and charges, respectively, based upon patient demographics, primary
payer, hospital characteristics, length of stay, Elixhauser comorbidities, preterm
labor, abnormalities in fetal heart rate/rhythm, and pre-eclampsia/eclampsia.
RESULTS: Overall, 14,190 inpatient cancer discharges in pregnant adults from
2005-2009 were observed. The mean maternal age was 30.36.5 years, with an
average length of stay being 5.07.8 days. The national bill summed to $434 mil-
lion, averaging $31,366 (71,765) per case. The most common cancers were Hodg-
kin’s disease and other lymphomas (27%), breast cancer (15%), leukemias (14%),
genitourinary cancers (14%), and thyroid/endocrine cancers (7%). Some 2,846 full-
term births and 2,140 premature births occurred; 321 inpatient fetal deaths/mis-
carriages were reported. In cases involving births, regression analyses found that
metastatic cancer, solid tumors, and pre-eclampsia/eclampsia were significantly
(p0.05) associated with preterm delivery. Increases in total charges were signifi-
cantly associatedwithmetastatic cancer, chronic blood loss anemia, hypertension,
and fluid/electrolyte disorders. CONCLUSIONS: Some 4986 births were observed
among pregnant adults with cancer during 2005-2009, with a large proportion in-
volving premature delivery. Continued research is warranted concerning theman-
agement and long-term implications of cancer and its treatment upon both moth-
ers and their surviving children.
PCN6
ARE QALY GAINS FOR NEW PHARMACEUTICALS INCREASING IN CANCER BUT
NOT OTHER DISEASES?
Thorat T, Chambers JD, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: Spending on pharmaceuticals as a proportion of total health care
spending is increasing. It is unclear, however, if this increase is translating into
increases in QALYs relative to standard care over time. Our objectives were to
evaluate incremental QALY gains reported in cost-utility studies published from
2000 through 2010; and to compare the findings for cancer and non-cancer related
pharmaceuticals.METHODS:We used the Tufts Medical Center Cost-Effectiveness
Analysis Registry (www.cearegistry.org) to identify cost-utility ratios for pharma-
ceuticals published from 2000- 2010. We considered incremental QALY gains, pub-
lication year, and source of study funding (drug manufacturer or other), for three
sets of analyses: all pharmaceuticals (n2277); cancer-related pharmaceuticals
(n235); and non-cancer related pharmaceuticals (n2042). We used multivariate
linear regression to evaluate the relationship between incremental QALY gains
(dependent variable) with study publication year (independent variable). We re-
garded p values below the 0.05 level of significance as statistically significant and
values between 0.05-0.1 as weakly significant. RESULTS: Adjusting for source of
study funding, in terms of the relationship between incremental QALY gains and
study publication year: for all pharmaceuticals, the estimated coefficient for pub-
lication year was negative (-0.015; p0.082); for non-cancer related pharmaceuti-
cals the estimated coefficient for publication year was negative, (-0.022, p0.017);
and, for cancer related pharmaceuticals, the estimated coefficient for publication
year was positive (0.069, p0.001). CONCLUSIONS: The results suggest that, in
contrast to the effectiveness of non-cancer related pharmaceuticals; the effective-
ness of cancer-related pharmaceuticals show increasing gains over time. That is,
incremental QALY gains for cancer-related drugs are increasing.
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LIFE EXPECTANCIES AND PROGNOSTIC FACTORS OF SURVIVAL IN PATIENTS
WITH DIFFERENT TYPES OF CANCER UNDER PROLONGED MECHANICAL
VENTILATION: A NATION-WIDE ANALYSIS OF 5,138 CASES DURING 1998-2007
Shih CY1, Hung MC2, Lu HM3, Chen L4, Wang JD5
1National Taiwan University Hospital Jin-shan Branch, New Taipei City, Taiwan, 2College of
Public Health, National Taiwan University, Taipei, Taiwan, 3National Health Research Institutes,
Zhunan, Taiwan, 4Institute of Population Health Sciences, National Health Research Institutes,
Zhunan, Taiwan, 5National Cheng Kung University, Tainan, Taiwan
OBJECTIVES: The aim of this study was to determine survival rate, life expectancy,
quality-adjusted life expectancy (QALE), and prognostic factors of cancer patients
of different organ-systems undergoing prolonged mechanical ventilation (PMV).
METHODS: We used data from the National Health Insurance Research Database
(NHIRD) of Taiwan, year of 1998 to 2007, and linked with the National Mortality
Registry to ascertain the mortality. A random sample of this population was per-
formed, and subjects who had continuously undergonemechanical ventilation for
longer than 21 days were enrolled in this study. We linked our dataset with the
registry of cancer under catastrophic illnesses of NHIRD. The life expectancies of
different organ-systems were estimated using a semi-parametric method with
assuming constant excess hazard and barrowing survival function of general pop-
ulation from the vital statistics of Taiwan. Multivariate proportional hazard model
was constructed to assess the effect of different prognostic factors, including age,
sex, organ-systems, comorbidities, hospital levels, and metastasis. Quality of life
data were taken from a sample of 142 patients under PMV and measured with
EQ-5D, which were classified into partial and poor cognitions. RESULTS: The anal-
ysis of 5138 cancer patients undergoing PMV revealed themedian survival was 1.37
months with a one-year survival rate of 14.3%. Head and neck cancer patients
seemed to survive the longest. The overall life expectancy was 1.21 years with
estimated QALE ranged from 0.16 to 0.36 quality-adjusted life years for patients
with poor and partial cognitions, respectively. Metastatic cancer status, cancer
type of lung and liver significantly predict a shorter survival independently.
CONCLUSIONS:Cancer patientswith PMVhad a poor long termoutcome. Palliative
care should be considered early in these patients with such a condition, especially
when metastasis occurred.
PCN8
PRIMARY ANDROGEN DEPRIVATION THERAPY VERSUS RADICAL
PROSTATECTOMY IN SEER-MEDICARE DATASET: A COMPARATIVE
EFFECTIVENESS ANALYSIS OF RETROSPECTIVE COHORTS
Liu J, Shi L, Sartor O, Culbertson R
Tulane University, New Orleans, LA, USA
OBJECTIVES: To examine the comparative effectiveness of primary androgen de-
privation therapy (PADT) and radical prostatectomy (RP).METHODS:Male patients
with localized prostate cancer (T1-T2, N0, M0) were identified in the SEER-Medicare
database from January 1998 to December 2007. Patients were 66-74 years old, with-
out other documented cancers, and had PADT initiation or RP within 6 months
after the first recorded diagnosis of prostate cancer in the dataset. PADT-treated
patients were 1:1 matched to the RP-treated patients via propensity score (PS)
matching. The overall survival from diagnosis to death was analyzed using Cox
proportional hazardmodels; prostate cancer specific survival examined using Fine
and Gray competing riskmodeling. The independent regression variables included
age at diagnosis, race, marital status, census regions, urban residence, clinical
cancer stage, Gleason score, prostate specific antigen level, Charlson comorbidity
index, calendar year at diagnosis, andhospitalization (yes or no), surgery (yes or no)
and outpatient visit (yes or no) during one year baseline period. RESULTS: The
PS-matched sample size was 3432 with mean age of 66.0 years. The baseline char-
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